Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.4% – Here’s Why

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares dropped 6.4% on Monday . The company traded as low as $63.50 and last traded at $63.7430. Approximately 317,916 shares traded hands during mid-day trading, a decline of 47% from the average daily volume of 595,805 shares. The stock had previously closed at $68.12.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Zacks Research cut Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 17th. Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 11th. HC Wainwright increased their price objective on Structure Therapeutics from $60.00 to $90.00 and gave the company a “buy” rating in a report on Friday, December 19th. Morgan Stanley lifted their target price on shares of Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Finally, Wall Street Zen upgraded shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $99.11.

Structure Therapeutics Stock Performance

The stock has a market capitalization of $3.81 billion, a PE ratio of -51.45 and a beta of -2.05. The business’s 50-day moving average is $47.01 and its two-hundred day moving average is $30.58.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). Equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of institutional investors have recently modified their holdings of the business. Balyasny Asset Management L.P. acquired a new stake in Structure Therapeutics in the third quarter valued at $12,923,000. Pacific Heights Asset Management LLC acquired a new stake in shares of Structure Therapeutics in the second quarter valued at about $9,540,000. Orbimed Advisors LLC boosted its holdings in Structure Therapeutics by 49.5% during the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after buying an additional 397,272 shares in the last quarter. Paradigm Biocapital Advisors LP acquired a new position in Structure Therapeutics during the third quarter worth about $10,440,000. Finally, Casdin Capital LLC raised its holdings in Structure Therapeutics by 26.9% during the third quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock worth $43,540,000 after purchasing an additional 330,000 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.